Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 4
Submit an article Journal homepage
400
Views
5
CrossRef citations to date
0
Altmetric
Letters to the Editor

Lenalidomide monotherapy leads to a complete remission in refractory B-cell post-transplant lymphoproliferative disorder

Heinz LäubliDepartment of Internal Medicine, Division of Medical Oncology, University Hospital Basel, Switzerland, ;Department of Biomedicine, Cancer Immunology Laboratory, University Hospital Basel, Switzerland, Correspondence[email protected]
,
Alexandar TzankovInstitute of Pathology, University Hospital Basel, Switzerland, and
,
Darius JuskeviciusInstitute of Pathology, University Hospital Basel, Switzerland, and
,
Lukas DegenDivision of Gastroenterology and Hepatology, University Hospital Basel, Switzerland
,
Christoph RochlitzDepartment of Internal Medicine, Division of Medical Oncology, University Hospital Basel, Switzerland,
&
Frank Stenner-LiewenDepartment of Internal Medicine, Division of Medical Oncology, University Hospital Basel, Switzerland, ;Department of Biomedicine, Cancer Immunology Laboratory, University Hospital Basel, Switzerland,
Pages 945-948 | Received 12 May 2015, Accepted 11 Aug 2015, Published online: 08 Oct 2015

References

  • Parker A, Bowles K, Bradley JA, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS Guidelines. Br J Haematol 2010; 149: 693–705.
  • Heslop HE. How I treat EBV lymphoproliferation. Blood 2009; 114: 4002–4008.
  • Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011; 29: 200–207.
  • Portell C, Nand S. Single agent lenalidomide induces a response in refractory T-cell posttransplantation lymphoproliferative disorder. Blood 2008; 111: 4416–4417.
  • Kritharis A, Coyle M, Sharma J, et al. Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities. Blood 2015; 125: 2471–2476.
  • Thieblemont C, Delfau-Larue MH, Coiffier B. Lenalidomide in diffuse large B-cell lymphoma. Adv Hematol 2012; 2012: 861060.
  • Hitz F, Fischer N, Pabst T, et al. Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial. Ann Hematol 2013; 92: 1033–1040.
  • Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 2013; 27: 1902–1909.
  • Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2008; 26: 4952–4957.
  • Zinzani PL, Pellegrini C, Gandolfi L, et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk 2011; 11: 462–466.
  • Tzankov A, Meier C, Hirschmann P, et al. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma. Haematologica 2008; 93: 193–200.
  • Witzig TE, Nowakowski GS, Habermann TM, et al. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann Oncol 2015; 26: 1667–1677.
  • Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol 2011; 22: 1622–1627.
  • Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011; 117: 5058–5066.
  • Nowakowski GS, LaPlant B, Macon WR, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol 2015; 33: 251–257.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.